23. ANALYSIS OF INPATIENT TREATMENT FOR HYPERTENSIVE PATIENTS AT TAM DAO HEALTH CENTER IN 2024-2025
Nội dung chính của bài viết
Tóm tắt
Objectives: To conduct an in-depth analysis of inpatient management patterns and clinical characteristics among hypertensive patients admitted to Tam Dao Health Center between 2024 and 2025.
Methods: A retrospective cross-sectional descriptive study was performed, encompassing all hospitalization episodes of patients diagnosed with arterial hypertension at Tam Dao Health Center from June 2024 to June 2025. Data were systematically extracted from electronic health records via the eMRHIS platform. Key variables included the total number of pharmacological agents prescribed, duration of hospitalization, presence of comorbid conditions, and utilization of antihypertensive agents across the five principal therapeutic drug classes.
Results: A total of 333 inpatient episodes involving hypertensive patients were analyzed. Length of stay ranged from 1 to 17 days, with the majority of admissions lasting between 1 and 8 days. Patients received between 1 and 10 pharmacological agents per hospitalization. The prevalence of comorbidities was 37.2%, with cardiovascular diseases accounting for 16.5% and dyslipidemia 13.8% of cases. The most frequently prescribed antihypertensive classes were calcium channel blockers (73.57%), diuretics (69.37%), and angiotensin-converting enzyme inhibitors (34.83%).
Conclusion: This study provides a comprehensive epidemiological and pharmacotherapeutic profile of hypertensive inpatients at a district-level healthcare facility. Findings underscore the clinical complexity of hypertension management in the inpatient setting, highlighting significant rates of polypharmacy and multimorbidity. The results advocate for the implementation of risk-stratified therapeutic approaches and contribute practical evidence to inform guideline-concordant blood pressure management in primary and secondary care settings.
Chi tiết bài viết
Từ khóa
Arterial hypertension, inpatient management, pharmacotherapy utilization, comorbidity profile, Tam Dao Health Center
Tài liệu tham khảo
[2] Cooper RS, Amoah AG, Mensah GA. High blood pressure. Ethnicity & Disease. 2003;13:48-52.
[3] World Health Organization. Global report on hypertension: the race against a silent killer. Geneva: World Health Organization; 2023.
[4] World Health Organization. National Survey on the Risk Factors of Non-Communicable Diseases in Vietnam, 2021. Geneva: World Health Organization; 2025.
[5] Carey RM, Moran AE, Whelton PK. Treatment of hypertension: a review. JAMA. 2022;328(18):1849-61.
[6] Nguyen Thanh Xuan, Nguyen Van Luyen, Nguyen Duy Toan. Relationship between hypertension, multimorbidity, and hospital stay duration among elderly patients. Vietnam Medical Journal. 2025;547(3):136-140.
[7] Nguyen Truong Son, Luong Ngoc Khue, Pham Manh Hung, Nguyen Lan Viet. Guidelines for the diagnosis and treatment of lower extremity arterial disease. Vietnam Journal of Cardiology. 2022;(102):5-19.
[8] Vu Tri Thanh, Hoang Thy Nhac Vu, Ha Chau Hung, Nguyen Duc Tung, Chung Khang Kiet. Analysis of inpatient treatment for hypertensive patients at Thu Duc City Hospital in 2024. Journal of Community Medicine. 2025;66(3):29-34.
[9] Tran Thai Ha, Tran Dinh Thang. Study on antihypertensive and antidiabetic drug use in hypertensive patients with type 2 diabetes. Journal of 108-Clinical Medicine and Pharmacy. 2021:188-197.
[10] Luu Hong Lien, Nguyen Chi Linh, Nguyen Thi Ngoc Ha, Dang Duy Khanh. Study on the status and rationality of antihypertensive drug use in outpatients at Bac Lieu General Hospital in 2021-2022. Vietnam Medical Journal. 2022;520(1B):84-88.